Biotech

All Articles

BMS axes bispecific months after submitting to work stage 3 trial

.Bristol Myers Squibb has possessed a whiplash change of heart on its BCMA bispecific T-cell engager...

Charles Baum manages Terremoto as CEO

.Charles Baum, M.D., Ph.D., that managed Mirati Rehabs' $ 5.8 billion sale to Bristol Myers Squibb l...

Asarina to shut after initiatives to partner Tourette's medication fall short

.After connecting to much more than 200 firms to partner a Tourette syndrome therapy that showed the...

Novartis pens $150M ahead of time bispecifics manage Dren Biography

.Novartis has actually possessed some bad luck along with bispecific antibodies in the past, but det...

AstraZeneca plants an EGFR tree with Pinetree package worth $45M

.Pinetree Therapeutics are going to help AstraZeneca vegetation some plants in its pipeline along wi...

GRO rounds up $60M series B to take gout arthritis therapy in to facility

.GRO Biosciences has finished the week along with an additional $60.3 million in the financial insti...

Chutes &amp Ladders-- Gilead's Merdad Parsey goes, Cassava drops chief executive officer

.Invite to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, firings ...